Maninder Hora is VP at NEKTAR THERAPEUTICS (NKTR). They have made 17 open-market trades across 1 company since 2016, most recently 2019-05-16.
CIK 0001443159
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 17 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTR | SELL | 2019-05-16 | 2019-05-17 | $31.37 | $154K | +0.5% | +5.5% | -43.0% |
| NKTR | SELL | 2019-02-19 | 2019-02-21 | $42.39 | $202K | -5.4% | -20.2% | -17.5% |
| NKTR | SELL | 2018-11-16 | 2018-11-19 | $38.25 | $359K | +10.0% | -6.7% | +16.6% |
| NKTR | SELL | 2018-05-16 | 2018-05-18 | $83.39 | $677K | -6.3% | -31.8% | -30.0% |
| NKTR | SELL | 2018-04-10 | 2018-04-12 | $105.67 | $106K | -19.3% | -22.7% | -55.4% |
| NKTR | SELL | 2018-04-05 | 2018-04-09 | $103.36 | $4.0M | -14.6% | -26.3% | -55.0% |
| NKTR | SELL | 2018-02-16 | 2018-02-20 | $82.94 | $477K | +23.6% | +24.9% | +0.3% |
| NKTR | SELL | 2017-11-06 | 2017-11-08 | $25.07 | $257K | +51.6% | +76.4% | +157.3% |
| NKTR | SELL | 2017-10-05 | 2017-10-10 | $25.00 | $190K | +3.7% | +36.3% | +146.5% |
| NKTR | SELL | 2017-08-16 | 2017-08-18 | $19.32 | $114K | +8.6% | +25.8% | +150.2% |
| NKTR | SELL | 2017-05-16 | 2017-05-18 | $19.55 | $116K | +1.8% | -5.8% | -0.1% |
| NKTR | SELL | 2017-04-05 | 2017-04-07 | $21.70 | $3.9M | -5.0% | -10.9% | -3.1% |
| NKTR | SELL | 2017-02-16 | 2017-02-17 | $13.14 | $29K | +12.6% | +68.4% | +48.8% |
| NKTR | SELL | 2016-11-16 | 2016-11-18 | $13.96 | $23K | -13.7% | -7.4% | -7.4% |
| NKTR | SELL | 2016-08-16 | 2016-08-17 | $17.56 | $116K | -1.6% | +8.3% | -20.9% |
| NKTR | SELL | 2016-05-17 | 2016-05-18 | $13.58 | $11K | +13.8% | +9.4% | +29.1% |
| NKTR | SELL | 2016-02-17 | 2016-02-18 | $11.92 | $11K | +1.6% | +12.0% | +20.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.